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Abstract
Prostate, pancreatic, and head and neck carcinomas have a high propensity to invade nerves. Surgical resection is
a treatment modality for these patients, but it may incur significant deficits. The development of an imaging method
able to detect neural invasion (NI) by cancer cells may guide surgical resection and facilitate preservation of normal
nerves. We describe an imaging method for the detection of NI using a herpes simplex virus, NV1066, carrying tyro-
sine kinase and enhanced green fluorescent protein (eGFP). Infection of pancreatic (MiaPaCa2), prostate (PC3 and
DU145), and adenoid cystic carcinoma (ACC3) cell lines with NV1066 induced a high expression of eGFP in vitro. An
in vivo murine model of NI was established by implanting tumors into the sciatic nerves of nude mice. Nerves were
then injected with NV1066, and infection was confirmed by polymerase chain reaction. Positron emission tomogra-
phy with [18F]-2′-fluoro-2′-deoxyarabinofuranosyl-5-ethyluracil performed showed significantly higher uptake in NI than
in control animals. Intraoperative fluorescent stereoscopic imaging revealed eGFP signal in NI treated with NV1066.
These findings show that NV1066 may be an imaging method to enhance the detection of nerves infiltrated by can-
cer cells. This method may improve the diagnosis and treatment of patients with neurotrophic cancers by reducing
injury to normal nerves and facilitating identification of infiltrated nerves requiring resection.
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Introduction
Prostate, pancreatic, and head and neck carcinomas are among the
leading causes of cancer death in the United States. These tumors
are also notorious for their ability to invade nerves. More than 85%
of patients with pancreatic and prostate carcinomas and 60% of those
with adenoid cystic carcinomas present with neural invasion (NI) at
the time of diagnosis [1,2]. One of the main treatment modalities
available for these patients is surgical resection of the primary tumor
along with regional nerves suspected of being infiltrated by cancer [3].
Unfortunately, such treatment often causes major morbidity and im-
paired quality of life due to loss of nerve function. Erectile dysfunction,
urinary incontinence, facial numbness, facial paralysis, hoarseness, dys-
phagia, and dysarthria are a few examples of the morbidity associated
with neural injury as a consequence of radical tumor resection [4]. For
this reason, some patients are willing to compromise survival outcomes
in exchange for improved function when choosing therapy [5].
The decision to resect or preserve nerves in close proximity to the
tumor is often made intraoperatively. Because preoperative imaging
modalities have a limited ability to identify NI by cancers, the parame-
ters currently available for surgeons to determine if a nerve is invaded
by cancer include preoperative neurologic symptoms, tumor adherence
to nerves, and evidence of gross neural infiltration during surgery [6].
Because of limitations in the ability to accurately identify NI by cancers,
normal nerves may sometimes be resected, needlessly inflicting the
morbidity of lost nerve function. Conversely, the consequences of
not resecting a nerve infiltrated by cancer include higher rates of disease
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recurrence and reduced survival [7]. An imaging method to accurately
detect the presence of NI by cancer would be of significant value to the
surgeon facing this intraoperative dilemma.
Current imaging techniques for the detection of cancer dissemina-
tion along nerves are limited and can only detect gross tumor infil-
tration. There is currently no effective imaging modality to reliably
identify the presence and extent of NI by cancer [8]. A surgeon
might consider intraoperative biopsies and frozen-section pathology
assessment from sites of suspected nerve infiltration. However, this
technique itself may cause unnecessary nerve injury.
Oncolytic herpes simplex viruses (HSVs) are replication-competent
vectors that can selectively infect cancer sells. These viruses can rep-
licate within cancer cells and induce expression of specific transgenes
coded by the viral genome [9]. Previous studies have shown that
HSVs carrying the transgene for enhanced green fluorescent protein
(eGFP) can be used to image tumors by fluorescence microscopy
[10]. Our goal was to develop a reliable imaging method for the as-
sessment of NI by cancer using herpes vectors. Such a system may
potentially allow surgeons to identify and selectively target resection
of nerves infiltrated by cancer, preventing unnecessary neural injury
to nerves not involved by cancer.
The ability of an NV1066-based imaging to identify NI by prostate,
pancreatic, and head and neck carcinomas was assessed in this study.
Our results demonstrate that NV1066 can be used as a safe and effec-
tive imaging method allowing for the detection of nerves infiltrated by
cancer, both in a preoperative and intraoperative setting.
Materials and Methods
Cell Lines
The human pancreatic adenocarcinoma cell line MiaPaCa2, the
prostate cell lines PC3 and DU145, and the adenoid cystic carcinoma
cell line ACC3 were used. Cells were grown in F12K medium adjusted
to contain 1.5 g/l sodiumbicarbonate (PC3), in high-glucoseDulbecco’s
modified Eagle’s medium (MiaPaCa2 and DU145) and in Roswell
Park Memorial Institute (RPMI)-1640 medium (ACC3). All media
contained 10% fetal calf serum, penicillin, and streptomycin. Cells
were maintained in 5% CO2 in a 37°C humidified incubator.
Viruses
NV1066 is an oncolytic HSV whose construction was previously
described [10]. In brief, it is a replication-competent, attenuated her-
pes simplex type-1 viral strain (F′ strain) that expresses eGFP on in-
fection of cancer cells. The transgene for eGFP is inserted into the
deleted internal repeat sequence region under the control of a cyto-
megalovirus promoter. NV1066 is also deficient in the UL23 se-
quence, the internal repeat sequence containing single copies of
the viral genes ICP-4, ICP-0, and γ134.5. These genomic deletions
decrease viral virulence and enhance tumor specificity. Viruses were
propagated on Vero cells and titered by standard plaque assay.
NV1066 was provided by Medigene, Inc. (San Diego, CA).
In Vitro Model of NI
Mice (Balb/c, 4–6 weeks old) were anesthetized, and their dorsal
root ganglia (DRG) was implanted ∼500 μm adjacent to a colony of
carcinoma cells in growth factor–depleted Matrigel matrix (BD Bio-
sciences, Bedford, MA). Cultures were grown in media containing
10% fetal calf serum at 37°C and 5% CO2. NV1066 was injected
into the Matrigel in an area between the cancer colony and the DRG,
1 to 4 days before imaging.
In Vivo Model of NI
Six-week-old athymic nudemice (National Cancer Institute, Bethesda,
MD) were anesthetized with inhalational isoflurane for all proce-
dures. The left sciatic nerve was then exposed deep to the femoro-
coccygeus and biceps femoris muscles. Human carcinoma cells were
microscopically injected into the perineurium of the sciatic nerve, dis-
tal to the bifurcation of the tibial and common peroneal nerves. Slow
microinjection of 3 μl of cell suspension at a concentration of 1 ×
105 cell/μl was performed using a 10-μl Hamilton syringe over a
2-minute period. Seven days after establishment of intraneural tumors,
5 × 107 viral plaque-forming units (PFUs) of NV1066 or saline were
injected into the sciatic nerve. In some experiments, NV1066 was
injected into nerves without tumors. For histologic analysis, mice were
euthanized 48 hours after viral infection, the sciatic nerve excised,
frozen in Tissue Tek (Sakura Finetek, Torrance, CA) solution, and
cut into 8-μm-thick sections. Other groups were observed for up to
7 weeks for assessment of tumor response, nerve function, or signs
of morbidity.
Measures of Sciatic Nerve Function
Sciatic nerve function was measured weekly. The sciatic nerve in-
nervates the hind limb paw muscles. Functional measures for mon-
itoring tumor NI included: (1) Gross behavior — signs of motor
weakness or repetitive biting of the hind limb were monitored for
10 minutes once a week; and (2) Limb function — graded according
to hind limb paw response to manual extension of the body, with
scores ranging from 4 = normal to 1 = total paw paralysis.
Fluorescence Imaging
NV1066-infected cancer cells were imaged in vitro by fluorescence
microscopy. Cancer cells (5 × 104) were plated in four-well chamber
slides (Laboratory-Tek, San Diego, CA). After overnight incubation
at 37°C, cells were infected with NV1066 at a multiplication of in-
fection (MOI; the ratio of PFU to tumor cells) of 0.1 to 10. Cells
treated with phosphate-buffered saline served as controls. The cells
were examined at different time intervals using a microscope (Axio-
vert 400; Carl Zeiss, Oberkochen, Germany). The MetaMorph Sys-
tem (Universal Imaging, Downingtown, PA) was used for image
analysis and eGFP quantification. Cells were examined under a
bright field microscope with a 4′,6-diamidino-2-phenylindole fluo-
rescence filter to assess cellular and nuclear morphology and viability.
In vivo imaging was performed in both bright field and fluorescence
modes using a stereomicroscope (Olympus America, Melville, NY).
The excitation filter was fixed-passage through a 470 ± 40-nm wave-
length light because eGFP has a minor excitation peak at 475 nm. The
emission filter was fixed at 500 nm to accommodate the emission peak
of eGFP at 509 nm. The image-capture system consisted of a digital
CCD camera (Retiga EX; Qimaging, Burnaby, Canada).
[18F]-FEAU Production
[18F]-FEAU (2′-fluoro-2′-deoxyarabinofuranosyl-5-ethyluracil)
was synthesized by coupling the radiolabeled fluoro sugar with the
silylated pyrimidine derivative following a procedure previously re-
ported by Serganova et al. [11]. The specific activity of the product
was ∼37 GBq/μmol (∼1 Ci/μmol); radiochemical purity was >95%
following purification by HPLC.
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Positron Emission Tomography
Animals were intravenously injected with ∼250 μCi (9.25 MBq)
of [18F]-FEAU tracer 2 hours before positron emission tomography
(PET) imaging. Mice were anesthetized with 2% isoflurane, de-
gutted, and imaged with a dedicated small-animal PET scanner
(Focus 120 micro-PET; Concorde Microsystems, Knoxville, TN)
[12]. Images were acquired using a transaxial field-of-view of 10 cm
and an axial field-of-view of 7.8 cm. An energy window of 350 to
750 keV and a coincidence timing window of 6 nanoseconds were
used. The resulting list-mode data were sorted into two-dimensional
histograms by Fourier rebinning, and transverse images were recon-
structed by filtered backprojection into a 128 × 128 × 63 (0.72 ×
0.72 × 1.3 mm3) matrix. Image analysis was performed using the
ASIPro software (Concorde Microsystems). After imaging, the speci-
mens were excised, weighed, and measured for radioactivity using
a gamma counter (Packard United Technologies, Downers Grove,
IL). The radioactivity is expressed as the percentage of radiotracer-
injected dose per gram of tissue (%[ID/g]). Animals were sacrificed
by CO2 inhalation.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Sciatic nerves of athymic nude mice were injected with NV1066
at 5 × 107 PFU or with saline for control animals. At 48 hours after
injection, mice were euthanized by CO2 inhalation. Brain, spinal
cord, and sciatic nerve tissues were excised and homogenized sepa-
rately in 1.2-ml TRIzol reagent (Invitrogen, Carlsbad, CA). After
the addition of chloroform, samples were centrifuged for phase sep-
aration. RNA was precipitated from the aqueous phase with isopro-
panol and treated with DNase (DNA-free; Ambion, Austin, TX)
according to the manufacturer’s directions. Complementary DNA
(cDNA) was reverse-transcribed from tissue RNA using random hex-
amer priming. For each sample, 250 to 500 ng of total RNA was
added to 4 μl of 5× RT buffer (Invitrogen), 10 pmol random hex-
amers, 12.5 μmol each of 2′-deoxyadenosine 5′-triphosphate, 2′-
deoxythymidine 5′-triphosphate, 2′-deoxyguanosine 5′-triphosphate,
and 2′-deoxycytidine 5′-triphosphate, 200 U of reverse transcriptase
(Invitrogen), and 20 U of RNasin (Promega, Madison, WI), bring-
ing the total volume to 20 μl. Quantitative reverse transcription–
polymerase chain reaction (RT-PCR) was performed on the total
RNA extracts from mice treated with saline or NV1066. It was
run in triplicate on a thermal cycler (ABI Prism 7700; Applied Bio-
systems, Foster City, CA) and contained cDNA, TaqMan Universal
PCR mix (Applied Biosystems), and target-specific TaqMan dye-
labeled primer/probe (Applied Biosystems). The primers used for
quantitative RT-PCR were for the expression of the early HSV-1 gene
ICP6 and late gene LAT. Each sample was measured quantitatively by
RT-PCR and standardized to an 18S ribosomal RNA (rRNA) con-
trol. Probes used for ICP6 included: ATA GCC AAT CCA TGA
CCC TGT ATG (forward), GGG TGG AGG CTG GGA GG (re-
verse), and CAC GGA GAA GGC GGA CGG GA (probe). Probes
used for LAT exon included: CCC ACG TAC TCC AAG AAG GC
(forward), AGA CCC AAG CAT AGA GAG CCA G (reverse), and
CCC ACC CCG CCT GTG TTT TTG TG (probe). Standard
curves were generated from serial dilutions. Reverse transcription–
polymerase chain reaction was performed under the following con-
ditions: stage 1, 50°C for 2 minutes; stage 2, 95°C for 10 minutes;
stage 3 (35 cycles), 95°C for 15 seconds and 60°C for 1 minute; and
stage 4, 25°C.
Statistical Analysis
Student’s t tests or analysis of variance (ANOVA) between group
were used for statistical analysis as appropriate. Mantle–Haenszel and
Fisher exact tests were used for evaluating differences in toxicity be-
tween groups. Differences were considered significant at P < .05. All
data are presented as mean ± SEM, unless indicated otherwise. All
experiments were repeated in triplicate. Data from representative ex-
periments are shown.
Results
NV1066 Infection Effectively Expresses eGFP in Cancer Cells
The ability of NV1066 to infect and express eGFP in DU145 and
PC3 (prostate carcinoma), ACC3 (salivary adenoid cystic carcinoma),
and MiaPaCa2 (pancreatic adenocarcinoma) cell lines was assessed
in vitro by fluorescence microscopy (Figure 1). All cells surviving by
day 6 showed nearly 100% eGFP expression following NV1066 infec-
tion at an MOI of 10 (ratio of viral PFU to cancer cells). Even at an
MOI of 1, the MiaPaCa2 and ACC3 cells showed nearly complete
eGFP expression by day 6. The four cell lines showed a similar pattern
of eGFP expression following NV1066 infection.
NV1066 Infection Selectively Expresses eGFP in Cancer Cells
But Not in Nerves
The effect of NV1066 on cancer cells in association with nerves was
evaluated using an in vitroNI model. Mouse DRG were implanted and
grown in Matrigel adjacent to a colony of cancer cell lines on a six-well
plate. Approximately 7 days after implantation, the DRG axons made
contact with the tumor colony, and NV1066 (5 × 107 PFU) was in-
jected into the Matrigel at this site. Twenty-four hours later, selective
eGFP expression by the cancer cells was detected using fluorescence
microscopy. This expression continued up to 5 days after infection (Fig-
ure 2). High-resolution microscopic images showed that neither the
neuronal cell bodies (ganglia) nor their axons expressed eGFP (n = 4).
Neither axonal growth nor nerve morphology was affected by the virus.
Intraneural Injection of NV1066 Allows Detection of
NI In Vivo
The safety of NV1066 injection into murine sciatic nerves was first
assessed. The left sciatic nerves of nude athymic mice were injected
with NV1066 or with wild-type HSV-1 (F′ strain) at 5 × 107 PFU.
The right sciatic nerves were injected with saline and served as con-
trols. Measures of nerve function were assessed daily. Mice treated with
NV1066 had normal sciatic nerve function and showed no change in
behavior relative to the controls for up to 30 days after treatment (n =
6). In comparison, all mice treated with the F′ strain showed complete
sciatic nerve paralysis within 4 days after treatment (n = 6) and died or
required euthanasia by day 7.
The ability of NV1066 to express eGFP selectively in nerves in-
vaded by cancer cells in vivo was evaluated. Tumors were established
in the sciatic nerves of nude mice bilaterally by direct injection of
3 × 105 pancreatic (MiaPaCa2), prostate (PC3 and DU145), or
adenoid cystic carcinoma (ACC3) cells into the distal portion of the
nerve. Seven days after the establishment of tumors, animals were
treated by an intraneural injection of 5 × 107 viral PFU of NV1066
or saline into the left sciatic nerve. In another group of mice, NV1066
was injected into normal sciatic nerves devoid of tumor cells. Two days
after viral infection, mice were anesthetized, their sciatic nerves
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exposed and inspected under a fluorescence dissecting stereoscope. A
strong eGFP signal was detected selectively in nerves infiltrated by can-
cer cells and treated with NV1066 (Figure 3). There was no fluores-
cence in intraneural tumors treated with saline or in normal sciatic
nerves devoid of cancer cells treated with NV1066 (n = 6). A strong
fluorescent signal was recorded for each neurotrophic cell lines (Fig-
ure 4). Fluorescence microscopy and hematoxylin and eosin staining
of nerve sections confirmed expression of eGFP selectively within the
nerves infiltrated by cancer cells. No eGFP expression was detected by
fluorescence microscopy in tumors treated with saline or in nerves
without tumors treated with NV1066.
[18F]-FEAU-PET Imaging with NV1066 Allows Detection
of NI In Vivo
Previous reports have suggested that PETmay be able to detect HSV
replication in vivo in cancer cells using [18F]-FEAU tracer as a substrate
for HSV-1 thymidine kinase [11–13]. We explored the possibility of
noninvasively imaging NI with PET following a single intraneural in-
jection of NV1066. Bilateral sciatic nerve tumors (PC3 or ACC3) were
treated with intraneural NV1066 injection (5 × 107 PFU) into the left
nerve tumor, whereas the right sciatic nerve tumor of the same animal
was injected with saline and served as control. Tumors treated with
NV1066 had significantly higher levels of [18F]-FEAU signal on the
Figure 1. Infection with NV1066 induces expression of enhanced green fluorescent protein (eGFP) in neurotrophic human carcinoma
cell lines in vitro. Human prostate carcinoma cells (PC3) were infected with NV1066 at a MOI of 1 for 5 days (A). Fluorescent microscopy
imaging showed eGFP expression within 24 hours after infection. The number of cells expressing eGFP gradually increased within the
next 6 days after infection (original magnification, ×100). The effect of various infection doses of NV1066 on eGFP expression by various
neurotrophic cell lines. Human prostate carcinoma cell lines DU145 (B) and PC3 (C), pancreatic carcinoma cell line MiaPaCa2 (D), and
salivary adenoid cystic carcinoma ACC3 (E). The cell lines were grown in culture for 6 days in the presence of various doses of NV1066.
Figure 2. NV1066 selectively induces enhanced green fluorescent protein (eGFP) expression in cancer cells but not in nerves in an
in vitro NI model. Dorsal root ganglia neurons were grown in Matrigel adjacent to a colony of cancer cells. NV1066 (5 × 107 PFU)
was injected into the Matrigel 5 days after implantation. Microscopic images were acquired 48 hours after infection using bright field
(A), fluorescence (B), and overlay (C) modes (original magnifications, ×40). High-magnification images illustrate that eGFP is expressed
selectively by the cancer cells. Arrowheads indicate nerve cells. The virus had no visible toxic effects on the nerves.
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PET scan than the contralateral tumors treated with saline (Figure 5, A
and B). Normal tissues and normal nerves devoid of cancer cells in-
jected with NV1066 showed PET signal similar to the background.
After imaging, the specimens were excised and further analyzed with
a gamma counter. Measurements of tissue radioactivity revealed a
>3.6-fold increase of [18F]-FEAU levels in the NV1066-treated nerves
compared to controls (n = 2 per group).
Quantitative RT-PCR was performed on the RNA extracts from
tumor specimens treated with NV1066 or saline. Primers for the HSV
ICP6 (early) and LAT (late) genes were used to assess viral infection. At
48 to 72 hours after viral injection, a significant increase in the relative
number of ICP6 and LATmRNA transcripts was detected in sciatic
nerves infiltrated by cancer cells but not in the brain or spinal cord of
these mice (Figure 5C ). No HSV mRNA transcripts were detected in
sciatic nerves infiltrated by cancer cells and treated with saline.
Discussion
Surgical therapy for carcinomas with NI ideally requires resection
of the tumor along with the involved nerves. In some cases, however,
it may be difficult to determine whether a nerve is actually invaded
by cancer, leaving surgeons with an intraoperative dilemma regarding
whether to excise or preserve a nerve with an unclear status. Palpation
and visual inspection of a nerve may not necessarily detect micro-
scopic invasion. The preservation of an invaded nerve is likely to in-
crease recurrence rates. Conversely, the resection of noninvaded
nerves may inflict significant and unnecessary morbidity to patients.
For prostate cancer, transection of the cavernous nerves causes erec-
tile dysfunction and urinary incontinence [4]. For head and neck
cancers, cranial nerve resection may cause blindness, facial nerve pa-
ralysis, facial numbness, hoarseness, dysphagia, dysarthria, and shoul-
der dysfunction [14,15]. The development of imaging methods for
detecting NI may have clinical utility by assisting surgeons to deter-
mine whether nerve resection is required and to identify the portion
of the nerve requiring resection. Furthermore, patients with NI often
require adjuvant radiation therapy to reduce the risk of tumor recur-
rence [16]. A reliable noninvasive method for detecting NI could as-
sist in targeting radiation therapy to areas where surgical resection is
not feasible [17]. The appropriate preservation of noninvaded nerves,
and treatment of nerves involved by cancer, may have a beneficial
impact on both functional and oncologic outcomes [18,19].
We hypothesized that herpes oncolytic therapy may be appropriate
for the clinical scenario of NI, as wild-type HSV-1 has a natural
trophism for infecting peripheral nerves. Green fluorescent protein
Figure 3. NV1066 selectively induces enhanced green fluorescent
protein (eGFP) expression in nerves infiltrated by cancer in an
in vivo NI model. Fluorescence image (A) and overlay image (B)
showing eGFP expression in PC3 prostate cancer cells invading
mouse sciatic nerves 48 hours after infection with NV1066 (5 ×
107 PFU). Nerves invaded by cancer that were treated with saline
had no fluorescence (C and D). Sciatic nerves without cancer inva-
sion that were treated with a similar dose of NV1066 had no fluo-
rescence (E and F).
Figure 4. NV1066 selectively localizes areas of nerve infiltration by
prostate and pancreatic carcinoma cells. Fluorescence image (A)
and overlay image of prostate carcinoma (DU145)–derived tumor
(B) and pancreatic carcinoma (MiaPaCa2)–derived tumor (C and D).
Fluorescence microscopy (E) and corresponding hematoxylin and
eosin image (F) of a sciatic nerve invaded by prostate carcinoma
cells (PC3) and treated with NV1066. Fluorescence microscopy (G)
and corresponding hematoxylin and eosin image (H) of a sciatic
nerve without tumor treated with NV1066. Enhanced green fluo-
rescent protein (eGFP) expression was found only in nerves infil-
trated by cancer but not in normal nerves. Panels A to D are
stereomicroscopic images. Panels E to H are microscopic images
(original magnifications, ×10).
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has previously been used as marker for retrovirus and herpes vector
gene transfer into various cancers including brain, mesothelioma, and
breast tumors [20,21]. Similar vectors were also used as molecular im-
aging modalities to target radioactive tracers into cancers [12,22]. In
this study, we demonstrate the utility of viral vectors to detect cancer
cells invading nerves through noninvasive PET imaging and real-time
fluorescence imaging. Using a genetically modified HSV-1, we dem-
onstrate that a single injection of an attenuated, replication-competent
vector can effectively express HSV-TK and eGFP in cancer cells invad-
ing nerves. All nerves infiltrated by tumors showed significant [18F]-
FEAU uptake capable of distinguishing between normal nerves and
nerves infiltrated by cancer 48 hours after a single administration of
NV1066. Intraoperatively, nerves infiltrated by tumor had significantly
higher fluorescent signal compared with normal nerves. We also dem-
onstrate that treatment with NV1066 had no adverse effect on nerve
function and did not disseminate to the central nervous system. These
findings suggest that NV1066 may safely be applied to effectively iden-
tify nerves infiltrated by cancer.
An implication of this study is that viral vectors might potentially
be used as an imaging adjunct to guide the treatment of NI. Preopera-
tive application of eGFP-expressing viruses could be performed before
surgery through image-guided intraneural injections. For example,
delivery could be performed through transrectal ultrasound-guided
injections to cavernous nerve bundles in patients with prostate can-
cer [23]. Imaging of eGFP expression could then be visualized with
fluorescent endoscopic imaging techniques [24]. Detection of small
cancer foci with NV1066 appears highly sensitive, because all of the
NV1066-treated cancers expressed HSV-TK or green fluorescent pro-
tein within 5 days. Furthermore, normal tissues failed to demonstrate
background fluorescence. The sensitivity of this method to detect
minimally invasive disease within nerves less than 0.5 mm in diameter
is likely to be better than conventional imaging techniques (computed
tomography, magnetic resonance imaging) that have resolutions able to
detect gross tumor infiltration [25].
Nerve grafting may result in partial return of function in patients
who require nerve resection due to cancer invasion. The only cur-
rent means of assessing the length of tumor invasion along the nerve
is nerve biopsy that requires resection of an additional nerve seg-
ment. Furthermore, because neurotrophic cancers may have skipped
areas along invaded nerves, negative pathologic findings at the nerve
margin does not guarantee complete cancer resection [26,27]. The
proposed method in this study might allow the surgeon to visually
delineate the extent of NI and to potentially detect varying sites of
cancer longitudinally along nerves. Such an assessment may further
assist adequate neural resection and facilitate decisions regarding graft
reconstruction or adjuvant therapy [16].
None of the NV1066-treated animals suffered from clinically ap-
parent side effects attributable to viral administration. The parent
Figure 5. [18F]-FEAU–PET imaging with NV1066 allows detection of cancerous NI in vivo. PET scanning of a mouse with bilateral ACC3
(A) or PC3 (B) tumors infiltrating the sciatic nerves. In each mouse, the left sciatic nerve was injected with NV1066 48 hours earlier, and
the right nerve was injected with saline as a control. The NV1066-treated tumors had significantly higher uptake of [18F]-FEAU (admin-
istrated by tail vein injection) on the PET scan. The bars on the right represent the accumulation of the radiotracer measured by a gamma
counter in each nerve (orange – left nerve; blue – right nerve). The NV1066 treated nerves had a greater than 3.6-fold increase of radio-
tracer uptake than the right nerve. Normal tissue infected with NV1066 had no significant [18F]-FEAU uptake. R indicates right side;
L, – left side (C). RT-PCR performed at 72 hours after viral infection showing that early (ICP6) and late (LAT ) viral mRNA were detected
in sciatic nerves infiltrated by tumor cells, but not in the brain, spinal cord, or saline-treated nerves (controls).
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virus from which NV1066 was derived, R7020, has a very favorable
safety profile in Aotus owl monkeys, a primate exquisitely sensitive to
herpes viral infections [28]. Even at a 10,000-fold higher dose than
wild-type HSV-1, R7020 remained less toxic to Aotus monkeys as
compared with HSV-1. A similar virus, NV1020, was recently stud-
ied in a phase I trial for patients with hepatic colorectal metastases.
Doses of up to 1.3 × 109 PFU were administered by hepatic infusion
pump without dose-limiting toxicity or significant adverse events at-
tributable to the virus [29]. NV1020 has a highly favorable safety
profile, a finding that has encouraged our investigation of its related
vectors such as NV1066 for clinical application.
In conclusion, our study shows that an attenuated, replication-
competent, herpes virus expressing eGFP can effectively and selectively
detect NI by cancer cells both in preoperative and intraoperative
setups. These findings hold significant clinical implications for poten-
tially improving patient care by enabling (1) the detection of nerves
infiltrated by cancer, (2) the selective preservation of normal nerves,
(3) the potential delineation of the extent of neural infiltration, and
(4) the guidance of adjuvant radiation therapy to areas not surgically
accessible. This novel imaging approach might potentially improve the
treatment of prostate, pancreatic, or head and neck cancers by preserv-
ing neural function and enhancing therapy of NI, potentially leading
to reduced morbidity and improved oncologic outcomes.
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